The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | ELARA: tisa-cel shows promise for follicular lymphoma
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses promising results from the ongoing Phase II ELARA trial (NCT03568461) investigating the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) for follicular lymphoma. Early data has shown that tisa-cel is well-tolerated and achieves durable complete remissions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
